Benjamin Hohl - 13 Feb 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
15 Feb 2024, 20:54:11 UTC
Prior SEC filing
31 Jan 2024
Next SEC filing
29 Feb 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Benjamin Hohl
Filing notes and source

Key filing fact

Benjamin Hohl filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 15 Feb 2024.

Key facts

  • This page summarizes Benjamin Hohl's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 15 Feb 2024, 20:54.

Change

  • Previous filing in this sequence was filed on 31 Jan 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELVN transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+185,000
Change %
Price
$0.000000
Shares after
185,000
Date
13 Feb 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
185,000
Exercise price
$14.85
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/4th of the shares subject to the option will vest on February 13, 2025 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .